Giant Biogene Holding Co. Ltd. (HK:2367)
:2367
Want to see HK:2367 full AI Analyst Report?
Top Page
Giant Biogene Holding Co. Ltd.
(2367)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$34.00
▲(18.22% Upside)
Action:Upgraded
Date:05/02/26
The score is driven primarily by strong financial quality (high profitability, solid cash generation, and extremely low leverage), partially offset by the 2025 slowdown in revenue/earnings. Technicals are neutral-to-weak versus key longer-term moving averages, while valuation is reasonable with a mid-teens P/E and a moderate dividend yield.
Positive Factors
High Profitability
Very high gross and net margins indicate durable pricing power and efficient cost structure in core bioactive ingredient and consumer products lines. Sustained operating profitability supports reinvestment in R&D and product development, underpinning long-term cash generation and competitive resilience.
Negative Factors
Revenue Decline (2025)
A one-year 12% revenue drop and lower net income point to material demand softness after prior expansion. If structural rather than cyclical, slower top-line growth reduces the runway for margin recovery, R&D reinvestment and long-term return expansion, pressuring future profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
Very high gross and net margins indicate durable pricing power and efficient cost structure in core bioactive ingredient and consumer products lines. Sustained operating profitability supports reinvestment in R&D and product development, underpinning long-term cash generation and competitive resilience.
Read all positive factors
Giant Biogene Holding Co. Ltd. (2367) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$29.50B
Dividend Yield1.84%
Average Volume (3M)12.22M
Price to Earnings (P/E)11.1
Beta (1Y)1.26
Revenue Growth-0.47%
EPS Growth-11.25%
CountryHK
Employees1,758
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)1.83
Shares Outstanding1,061,704,000
10 Day Avg. Volume16,417,830
30 Day Avg. Volume12,220,358
Financial Highlights & Ratios
PEG Ratio-1.28
Price to Book (P/B)3.19
Price to Sales (P/S)5.73
P/FCF Ratio21.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$40.06Price Target Upside39.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.86
Revenue Forecast (FY)HK$6.15B
Giant Biogene Holding Co. Ltd. Business Overview & Revenue Model
Company Description
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginseno...
How the Company Makes Money
null...
Giant Biogene Holding Co. Ltd. Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.52B | 5.54B | 3.52B | 2.36B | 1.55B |
| Gross Profit | 4.43B | 4.55B | 2.95B | 2.00B | 1.35B |
| EBITDA | 2.19B | 2.31B | 1.78B | 1.21B | 933.64M |
| Net Income | 1.91B | 2.06B | 1.45B | 1.00B | 828.13M |
Balance Sheet | |||||
| Total Assets | 10.85B | 8.04B | 4.97B | 3.14B | 7.88B |
| Cash, Cash Equivalents and Short-Term Investments | 8.29B | 5.86B | 3.78B | 2.20B | 7.26B |
| Total Debt | 9.69M | 6.71M | 2.73M | 2.59M | 0.00 |
| Total Liabilities | 917.03M | 918.14M | 602.03M | 301.19M | 6.86B |
| Stockholders Equity | 9.92B | 7.11B | 4.36B | 2.83B | 1.02B |
Cash Flow | |||||
| Free Cash Flow | 1.48B | 1.79B | 1.42B | 778.39M | 581.21M |
| Operating Cash Flow | 1.90B | 2.04B | 1.65B | 931.64M | 692.40M |
| Investing Cash Flow | -471.99M | -1.11B | -527.28M | -858.74M | 1.56B |
| Financing Cash Flow | 892.40M | 582.95M | 51.81M | -5.79B | 4.48B |
Giant Biogene Holding Co. Ltd. Technical Analysis
Negative
28.76
Price Trends
29.89
Negative
31.91
Negative
40.39
Negative
Market Momentum
-0.29
Positive
37.94
Neutral
7.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2367, the sentiment is Negative. The current price of 28.76 is below the 20-day moving average (MA) of 30.48, below the 50-day MA of 29.89, and below the 200-day MA of 40.39, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 37.94 is Neutral, neither overbought nor oversold. The STOCH value of 7.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2367.
Giant Biogene Holding Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | HK$3.16B | 13.29 | 6.65% | 5.90% | 8.92% | 9.50% | |
74 Outperform | HK$29.50B | 11.11 | 19.93% | 1.84% | -0.47% | -11.25% | |
66 Neutral | HK$16.26B | 11.44 | 42.05% | 2.53% | 35.28% | 41.20% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | HK$30.11B | 6.24 | 11.65% | 5.36% | 1.76% | 10.34% | |
51 Neutral | HK$17.82B | 37.15 | -4.30% | 5.00% | -1.71% | 53.04% | |
48 Neutral | HK$930.98M | -702.74 | -12.38% | ― | 52.36% | ― |
* Consumer Defensive Sector Average
HK:2367
Giant Biogene Holding Co. Ltd.
28.00
-54.94
-66.24%
HK:1044
Hengan International Group Co
26.04
4.97
23.58%
HK:0157
Natural Beauty Bio-Technology
0.47
-0.03
-7.00%
HK:6601
Cheerwin Group Limited
2.36
-0.14
-5.49%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
40.28
-29.87
-42.58%
HK:6993
Blue Moon Group Holdings Ltd.
3.02
-0.64
-17.49%
Giant Biogene Holding Co. Ltd. Corporate Events
Giant Biogene Moves to Replace EY With KPMG as Auditor
Apr 30, 2026
Giant Biogene Holding Co. Ltd. has launched a planned change of auditors as part of its corporate governance review, deciding not to reappoint Ernst Young after seven consecutive years of auditing its consolidated financial statements. EY will co...
Giant Biogene Reshapes Corporate Secretariat With New Joint Company Secretary
Apr 8, 2026
Giant Biogene Holding Co. Ltd. announced that joint company secretary and authorised representative Ms. Yuen Wing Yan, Winnie has resigned from her roles, including as the company’s process agent in Hong Kong, effective 8 April 2026, with no...
Giant Biogene Posts Flat Revenue but Lower Profit and Maintains Robust Dividends for 2025
Mar 19, 2026
Giant Biogene Holding Co., Ltd., a Hong Kong-listed biotechnology group, focuses on bio-based products and related life sciences technologies, and prepares audited consolidated financial statements in accordance with IFRS. The company operates thr...
Giant Biogene Proposes Final Dividend for 2025 Financial Year
Mar 19, 2026
Giant Biogene Holding Co., Ltd. has proposed a final ordinary cash dividend of RMB 0.539 per share for the financial year ended 31 December 2025, underscoring its intention to return capital to shareholders. The dividend, subject to shareholder ap...
Giant Biogene Announces Special 2025 Dividend, Signaling Confidence in Cash Position
Mar 19, 2026
Giant Biogene Holding Co., Ltd. has declared a special cash dividend of RMB 0.6714 per share for the financial year ended 31 December 2025, underscoring management’s willingness to return excess capital to shareholders. The dividend, subject...
Giant Biogene Sets March Board Meeting to Approve 2025 Results
Mar 5, 2026
Giant Biogene Holding Co. Ltd. has scheduled a board meeting for 19 March 2026 to review and approve the group’s audited financial results for the year ended 31 December 2025. The board will also consider whether to recommend a final dividen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.